Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicholas Piramal Buys Two Brand Groups From India’s Khandelwal

This article was originally published in PharmAsia News

Executive Summary

Khandelwal Laboratories has agreed to sell two of its brand divisions to Nicholas Piramal in an all-India deal. The deal for Anatortan and CEFI brand groups includes use of certain patents and a non-competing agreement by Nicholas Piramal for a pair of key Khandelwal drugs. The purchase of Anatortan and CEFI was put at $29 million. Nicholas Piramal expects to take advantage of its national sales and distribution network to market the formerly Khandelwal brands. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts